详细介绍
CAM5.2低分子细胞角蛋白(鼠单克隆抗体)
广州健仑生物科技有限公司
细胞角蛋白是一种常用的肿瘤免疫组织化学标记物,阳性表达见于上皮细胞、间皮细胞;癌间皮瘤等。细胞角蛋白(cytokeratin CK)主要分布于上皮细胞,是角质细胞中的主要骨架蛋白,这种结构蛋白的主要功能是维持上皮组织的完整性及连续性。研究发现细胞角蛋白(CK)具有*的保守性和组织分化特异性,与上皮细胞的增殖分化密切相关。目前已得到证实的细胞角蛋白有20多种。
我司还提供其它进口或国产试剂盒:登革热、疟疾、流感、A链球菌、合胞病毒、腮病毒、乙脑、寨卡、黄热病、基孔肯雅热、克锥虫病、违禁品滥用、肺炎球菌、军团菌、化妆品检测、食品安全检测等试剂盒以及日本生研细菌分型诊断血清、德国SiFin诊断血清、丹麦SSI诊断血清等产品。
欢迎咨询
欢迎咨询
【产品介绍】
细胞定位:细胞浆
克隆号:CAM5.2
适用组织:石蜡/冰冻
阳性对照:直肠癌/肺腺癌
抗原修复:热修复(EDTA)
抗体孵育时间:30-60min
产品编号 | 抗体名称 | 克隆型别 |
OB028 | Calponin-1(肌动蛋白结合蛋白) | EP798Y |
OB029 | Calretinin (钙视网膜蛋白) | 2E7 |
OB030 | CR(Calretinin) (钙视网膜蛋白) | polyclonal |
OB031 | CAM5.2(低分子细胞角蛋白) | CAM5.2 |
OB032 | CD10(共同型急性淋巴细胞白血病抗原) | 56C6 |
OB033 | CD117(酪氨酸激酶生长因子受体蛋白) | YR145 |
OB034 | CD11c(整合素α链蛋白) | 5D11 |
OB035 | CD138(肝素硫酸酯蛋白聚糖) | B-A38 |
OB036 | CD13(细胞膜表面糖蛋白) | SP187 |
OB037 | CD14(单核细胞) | EPR3653 |
OB038 | CD15(粒细胞) | MMA |
OB039 | CD163(M130抗原) | MRQ-26 |
OB040 | CD19(B细胞、滤泡树突状细胞) | MRQ-36 |
OB041 | CD19(B细胞、滤泡树突状细胞) | EP169 |
CAM5.2低分子细胞角蛋白(鼠单克隆抗体)
预防以自动免疫为主,在我国常用白百破(白喉类毒素、百日咳杆菌Ⅰ相灭活菌苗、破伤风类毒素,DPT)三联菌苗,接种对象为一岁以下幼儿。接种后能显著降低发病率和死亡率。但目前使用的死菌苗在一定的副作用,在安全性、免疫原性方面均有进一步改进的必要。
治疗可用红霉素、氨苄青毒素等。 百日咳杆菌
急性传染病百日咳的病原菌。
1906年,比利时细菌学家和免疫学家鲍台和让古发现,又称鲍--让杆菌。他们同时发明了百日咳杆菌菌苗。他们在研究中发现,百日咳杆菌含有对热不稳定物质,将其注入豚鼠和家兔腹腔或静脉中,能将动物杀死。如给皮下注射则产生皮肤坏死。从有病的孩子临床表现以及百日咳菌苗的副作用等均表明百日咳杆菌具有特殊的致病物质。以后许多学者从各个侧面研究百日咳杆菌的致病物,又陆续发现该菌含有多种生物学活性物质,其中有些物质与治病作用密切相关。近年来,日本、美国等许多学者已经研究制备百日咳无细胞菌苗代替全细胞菌苗,可显著减低全细胞菌苗的毒性反应。由于百日咳是一种常见的呼吸道感染病,所以应广泛地进行百日咳菌苗预防接种,一般新生儿生后三个月即可注射百日咳菌苗。由于百日咳菌苗的毒性反应使特异预防受到限制,应加速研抗原抗体性低免疫效果好的无细胞菌苗
病因
由刚地弓形虫所引起,呈流行。特殊人群如肿瘤患者、免疫抑制或免疫缺陷患者、先天性缺陷婴幼儿感染率较高。
临床表现
一般分为先天性和后天获得性两类,均以隐抗原抗体染为多见。临床症状多由新近急抗原抗体染或潜在病灶活化所致。
先天性弓形虫病的临床表现复杂。多数婴儿出生时可无症状,其中部分于出生后数月或数年发生视网膜脉络膜炎、斜视、失明、癫痫、精神运动或智力迟钝等。下列不同组合的临床表现:视网膜脉络膜炎、脑积水、小头畸形、无脑儿、颅内钙化等应考虑本病可能。
CAM5.2
我司还提供其它进口或国产试剂盒:登革热、疟疾、流感、A链球菌、合胞病毒、腮病毒、乙脑、寨卡、黄热病、基孔肯雅热、克锥虫病、违禁品滥用、肺炎球菌、军团菌、化妆品检测、食品安全检测等试剂盒以及日本生研细菌分型诊断血清、德国SiFin诊断血清、丹麦SSI诊断血清等产品。
想了解更多的产品及服务请扫描下方二维码:
【公司名称】 广州健仑生物科技有限公司
【市场部】 杨永汉
【】
【腾讯 】
【公司地址】 广州清华科技园创新基地番禺石楼镇创启路63号二期2幢101-103室
Prevention of autoimmune mainly diphtheria broken (diphtheria toxoid, B. pertussis phase I inactivated vaccine, tetanus toxoid, DPT) triple bacterins commonly used in our country, vaccinated objects for children under one year of age. Inoculation can significantly reduce morbidity and mortality. However, the current use of dead bacterin in some side effects, both in terms of safety, immunogenicity have the need for further improvement.
Erythromycin can be used for treatment, such as ampicillin. Bordela pertussis
Acute infectious disease Pertussis pathogens.
In 1906, the Belgian bacteriologist and immunologist Bao Tai and Jean ancient found, also known as abalone - let bacillus. They also invented the Bordela pertussis vaccine. In their study, they found that Bordela pertussis contains a heat-labile substance that can be injected into the abdominal cavity or vein of guinea pigs and rabbits to kill the animal. Skin subcutaneous injection can cause skin necrosis. From the clinical manifestations of sick children and the side effects of pertussis vaccine, etc. have shown that Bordela pertussis has a special pathogenic substances. Since then, many scholars have studied the pathogens of Bordela pertussis from various aspects and have successively discovered that the bacterium contains many kinds of biological active substances. Some of these substances are closely related to the therapeutic effect. In recent years, Japan, the United States and many other scholars have studied the preparation of acellular pertussis acellular vaccine instead of whole cell vaccine can significantly reduce the toxicity of whole cell vaccine. Because of whooping cough is a common respiratory disease, it should be carried out widely vaccination pertussis vaccine, the general neonatal three months after birth can be injected pertussis vaccine. Due to the pertussis vaccine toxicity response to specific prevention is limited, should accelerate the research of antigen-antibody low immune effect of acellular cell vaccine
Etiology
Toxoplasma gondii caused by the global epidemic. Special populations such as cancer patients, immunosuppressed or immunodeficient patients, high incidence of congenital infantile infection.
Clinical manifestations
Generally divided into two types of acquired congenital and acquired are hidden anti-antigen antibody is more common. Clinical symptoms and more by the recent acute antigen antibody staining or potential lesions caused by activation.
The clinical manifestations of congenital toxoplasmosis are complex. Most babies are asymptomatic at birth, and some of them occur retinal choroiditis, strabismus, blindness, epilepsy, mental retardation, mental retardation, etc. months or years after birth. The following different combinations of clinical manifestations: retinal choroiditis, hydrocephalus, microcephaly, no brain, intracranial calcification, etc. should consider the possibility of this disease.